Effectiveness of adjustable maintenance dosing and fixed dosing with budesonide/formoterol single inhaler in a multi-ethnic asthma population Source: Eur Respir J 2004; 24: Suppl. 48, 311s Year: 2004
Adjustable dosing with budesonide/formoterol in a single inhaler reduces costs compared with a conventional fixed dosing regimen Source: Eur Respir J 2003; 22: Suppl. 45, 411s Year: 2003
Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with fixed dosing – 3-month study Source: International Congress 2017 – Clinical points to ponder in asthma Year: 2017
Scientific rationale for using a single inhaler for asthma control by comparison of the effectiveness and safety of formoterol/budesonide turbuhaler as physician-guided adjustable maintenance dosing regimen versus formoterol/budesonide given as fixed dose of twice daily therapy in the management of bronchial asthma Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009
Adjustable dosing with budesonide/formoterol achieves sustained guideline ‘well-controlled asthma‘ following step down in treatment Source: Eur Respir J 2005; 26: Suppl. 49, 50s Year: 2005
Benefits of adjustable versus fixed maintenance dosing of budesonide/formoterol: a Swiss study in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 258s Year: 2003
Effects of budesonide/formoterol combination therapy versus budesonide on airway dimensions in asthma Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2012
Adjustable maintenance treatment of asthma with budesonide and formoterol in a single inhaler Source: Eur Respir J 2002; 20: Suppl. 38, 397s Year: 2002
Inhaler device plays an important role for the patients‘ QOL to be improved by switching from short-acting anticholinergics to once-daily bronchodilator tiotropium in COPD Source: Eur Respir J 2006; 28: Suppl. 50, 429s Year: 2006
The ATACO study: adjustable maintenance therapy with budesonide and formoterol in a single inhaler Source: Eur Respir J 2002; 20: Suppl. 38, 41s Year: 2002
Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with fixed dosing – a 5-month study in Canada Source: Eur Respir J 2003; 22: Suppl. 45, 411s Year: 2003
Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus a higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone Source: Eur Respir J 2006; 28: Suppl. 50, 205s Year: 2006
Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008
Low-dose single-inhaler budesonide/formoterol administered once daily is effective in mild-persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 158s Year: 2001
Once-daily budesonide/formoterol via a single inhaler is effective in mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001
Add-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler Source: ERJ Open Res 2016: 00106-2015 Year: 2016
Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: an exploratory analysis of the RELIEF study in patients using formoterol as maintenance therapy Source: Eur Respir J 2002; 20: Suppl. 38, 44s Year: 2002
Comparison of two twice-daily doses of budesonide/formoterol maintenance and reliever therapy Source: Eur Respir J 2010; 36: 524-530 Year: 2010
Budesonide/formoterol in a single inhaler sustains lung-function improvements in COPD Source: Eur Respir J 2003; 22: Suppl. 45, 50s Year: 2003
Adjustable dosing with budesonide/formoterol in a single inhaler maintains improvement in health-related quality of life at a lower drug load than fixed dosing – the ATACO study Source: Eur Respir J 2003; 22: Suppl. 45, 258s Year: 2003